1. Home
  2. BOC vs FBRX Comparison

BOC vs FBRX Comparison

Compare BOC & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Omaha Corporation

BOC

Boston Omaha Corporation

HOLD

Current Price

$12.07

Market Cap

388.4M

Sector

N/A

ML Signal

HOLD

Logo Forte Biosciences Inc.

FBRX

Forte Biosciences Inc.

HOLD

Current Price

$32.42

Market Cap

487.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOC
FBRX
Founded
2009
N/A
Country
United States
United States
Employees
N/A
19
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
388.4M
487.2M
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
BOC
FBRX
Price
$12.07
$32.42
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$67.00
AVG Volume (30 Days)
124.8K
375.3K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.30
EPS
N/A
N/A
Revenue
$114,376,348.00
$36,000.00
Revenue This Year
$4.46
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.64
N/A
52 Week Low
$11.03
$4.91
52 Week High
$15.72
$35.80

Technical Indicators

Market Signals
Indicator
BOC
FBRX
Relative Strength Index (RSI) 45.45 61.85
Support Level $12.01 $26.67
Resistance Level $12.87 $35.62
Average True Range (ATR) 0.37 3.65
MACD 0.03 0.94
Stochastic Oscillator 60.86 75.41

Price Performance

Historical Comparison
BOC
FBRX

About BOC Boston Omaha Corporation

Boston Omaha Corp is a United States based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. Company generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.

About FBRX Forte Biosciences Inc.

Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

Share on Social Networks: